5 completed, 1 terminated. 4 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Single low dose cyclophosphamide: new trials by email Literature Review of Single low dose cyclophosphamide trials Research Report on Single low dose cyclophosphamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population Tecemotide, Single low dose cyclophosphamide, Placebo - Non-Small Cell Lung Cancer | Phase 3 | Terminated | Merck KGaA, Darmstadt, Germany | 285 | 2009-12-01 | 2016-10-26 |
| Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 178 | 2008-12-01 | 2015-10-21 |
| Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide - Multiple Myeloma | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 34 | 2008-01-01 | 2016-02-22 |
| Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo - Non-small Cell Lung Cancer | Phase 3 | Completed | EMD Serono | 1513 | 2007-01-01 | 2015-11-20 |
| Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best standard of care (BSC) - Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 22 | 2005-04-01 | 2015-08-18 |
| Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best Supportive Care (BSC) - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 171 | 2000-08-01 | 2015-11-18 |
Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (2) · Carcinoma (1) · Multiple Myeloma (1)
Merck KGaA, Darmstadt, Germany (5) · EMD Serono (1)
Germany (4) · China (2) · Hong Kong (2) · Singapore (2) · South Korea (2) · Taiwan (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1)
PMID 34870327, PMID 16170175, PMID 21071331, PMID 21744082, PMID 21982342, PMID 24331154, PMID 24976972, PMID 25483677, PMID 25722382